Furthermore, multiple Bcl-2 inhibitors are being tested in clinical studies against various cancer types [9,10], and activity has been widely reported in pre-clinical models such as human breast cancer cells MCF-7 [11,12] and MDA-MB-231 [13] and human lung cancer cell A549 [14,15]. The gene discussed is BCL2; the disease is cancer.